ADMA Biologics Faces Securities Fraud Lawsuit
ADMA Biologics is the subject of a class action lawsuit alleging violations of securities laws, specifically §§10(b) and 20(a). Investors may have until year-end to join.
ADMA Biologics (NASDAQ: ADMA) is facing a class action lawsuit alleging securities fraud. Law firm Schall, Brown & Schwartz LLP has notified investors of the suit, which claims violations of federal securities laws, including §§10(b) and 20(a).
The lawsuit alleges that ADMA Biologics and certain of its officers and directors engaged in a scheme to defraud investors and artificially inflate the company's stock price. Investors who purchased ADMA Biologics securities during a specific period may have suffered losses as a result of these alleged misrepresentations and omissions.
The legal action centers on allegations of undisclosed material facts and misleading statements made by the company. Investors seeking to participate in the lawsuit are encouraged to contact SBS Law for details on how to join the proceedings. A deadline for filing claims has been set.
ADMA Biologics focuses on the development and commercialization of plasma-derived biologics for the treatment of rare diseases. This lawsuit could impact the company's reputation and ongoing business operations.